Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002242924 | SCV001591191 | pathogenic | Autosomal dominant epilepsy with auditory features | 2020-12-30 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys36Asnfs*40) in the LGI1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LGI1 are known to be pathogenic (PMID: 24206907). This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with LGI1-related conditions. For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV002280182 | SCV002568579 | pathogenic | not provided | 2022-08-29 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Has not been previously published as pathogenic or benign to our knowledge; Not observed at significant frequency in large population cohorts (gnomAD) |
Mayo Clinic Laboratories, |
RCV002280182 | SCV004227206 | likely pathogenic | not provided | 2022-05-02 | criteria provided, single submitter | clinical testing | PM2, PVS1 |